GSK to get USD 1.25 billion from Gilead Sciences to settle dispute of HIV based drug unit Ruchika Sharma3 Feb 2022 2:44 PM ISTGilead will also pay a 3 percent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.
NIH celebrates FDA approval of long-acting injectable drug for HIV prevention Hina Zahid24 Dec 2021 9:00 AM ISTYesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare,...
GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 mln savita thakur thakur19 Dec 2015 1:05 PM ISTLondon: Pharmaceutical group GlaxoSmithKline said its majority-owned HIV drugs business would buy drugs at different stages of development from U.S....
Johnson & Johnson, ViiV Healthcare: Two injections every month or two could control HIV Pooja Bhatia Bhatia5 Nov 2015 9:07 AM ISTJohnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, has recently shared results from the first 32 weeks of the...
